Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: A meta-analysis

Arthritis Research and Therapy

Volumn 8, Issue 5, 2006, Pages

  Singh, Gurkirpal ^a,b   Wu, Olivia ^c   Langhorne, Peter ^c   Madhok, Rajan ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Institute of Clinical Outcomes Research and Education   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

HUMAN; META ANALYSIS; MYOCARDIAL INFARCTION; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 34548105468     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar2047     Document Type: Article

References (45)

1. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092-102.
2. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M, Adenoma Prevention with Celecoxib (APC) Study Investigators: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071-1080.
3. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, Boyce SW, Verburg KM: Complications of COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352 1081-1089.
4. Maxwell SRJ, Webb DJ: IOX-2 selective inhibitors: important lessons learnt. Lancet 2005, 365:449-451.
5. Krotz F, Schiele TM, Klauss V, Sohn HY: Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 2005, 42 312-324.
6. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: Population based nested case-control analysis. BMJ 2005, 330:1366.
7. Asano TK, McLeod RS: Non steroidal anti-inflammatory drugs (NSAID) and aspirin for preventing colorectal adenomas and carcinomas. Cochrane Database Syst Rev 2004, 2:CD004079.
8. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998, 104:413-421.
9. Kmet LM, Lee RC, Cook LS: Standard Quality Assessment Criteria for Evaluating Primary Research Papers From a Variety of Fields Alberta: Alberta Heritage Foundation for Medical Research; 2004.
10. NHS Centre for Review and Dissemination: Undertaking Systematic Reviews of Research on Effectiveness: CRD's Guidance for Those Carrying Out or Commissioning Reviews 2nd edition. York, UK: University of York; 2001.
11. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
12. Greenland S: Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987, 9:1-30.
13. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Strom BL: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005, 142:157-164.
14. Kimmel SE, Berlin JA, Reilly M, Jaskowiak J, Kishel L, Chittams J, Storm BL: The effects of non-selective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004, 43:985-990.
15. Jick SS: The risk of gastrointestinal bleed, myocardial infarction, and newly diagnosed hypertension in users of meloxicam, diclofenac, naproxen and piroxicam. Pharmacotherapy 2000, 20:741-744.
16. Watson DJ, Rhodes T, Cai B, Guess HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002, 162:1105-1110.
17. Garcia Rodriguez LA, Varas C, Patrono C: Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000, 11:382-387.
18. Fischer L, Schlienger RG, Matter CM, Jick H, Meir CR: Current use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction. Pharmacotherapy 2005, 25:503-510.
19. Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A, Gonzalez- Perez A: Non steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004, 109 3000-3006.
20. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study. Lancet 2005, 365:475-481.
21. Johnsen SP, Larsson H, Tarone RE, McLaughlin JK, Norgard B, Friis S, Sorensen HT: Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: A population-based case-control study. Arch Intern Med 2005, 165:978-984.
22. Levesque LE, Brophy JM, Zhang B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: A population study of elderly adults Ann Intern Med 2005, 142:481-489.
23. Mamdani M, Rochon P, Juurlink DN, Anderson GM, Kopp A, Naglie G, Austin PC, Laupacis A: Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003, 163:481-486.
24. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR: Cox-2 selective non steroidal anti-inflammatory drugs and risk of coronary heart disease. Lancet 2002, 360:1071-1073.
25. Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR: Non steroidal anti-inflammatory drugs and risk of serious coronary heart disease; an observational cohort. Lancet 2002, 359:118-123.
26. Rhame E, Pilote L, LeLorier J: Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002, [ 162:1111-1115.
27. Schlienger RG, Jick H, Meier CR: Use of non steroidal antiinflammatory drugs and the risk of first acute myocardial infarction Br J Clin Pharmacol 2002, 54:327-332.
28. Solomon DH, Glynn RJ, Levin R, Avorn J: Nonsteroidal antiinflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099-1104.
29. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger ML: Risk of cardiovascular events and rofecoxib: Cumulative metaanalysis. Lancet 2004, 364:2021-2029.
30. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343 1520-158.
31. Decision memo: Analysis and recommendations for agency action - COX-2 selective and non-selective NSAIDs1 [http:www.fda.gov/cder/drug/ infopage/cox2/NSAIDdecision memo.pdf]
32. Langman MJ, Weil J, Wainwright P, Lawson DH, Rawlins MD, Logan RF, Murphy M, Vessey MP, Colin-Jones DG: Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994, 343:1075-1078.
33. Jick H, Garcia Rodriguez LA, Perez-Gutthann S: Principles of epidemiological research on adverse and beneficial drug effects. Lancet 1998, 352:1767-1770.
34. Cross design synthesis: A new strategy for studying medical outcomes? [editorial]. Lancet 1992, 340:944-946.
35. Black N: Why we need observational studies to evaluate the effectiveness of health care. BMJ 1996, 312:1215-1218.
36. Pocock S, Elbourne DR: Randomized trials or observational tribulations. N Engl J Med 2000, 342:1907-1909.
37. Egger M, Schneider M, Davey Smith G: Spurious precision? Meta-analysis of observational studies. BMJ 1998, 316 140-144.
38. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF, et al.: Gastrointestinal toxicity with celecoxib vs non-steroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study. A randomised controlled trial. Celecoxib Longterm Arthritis Safety Study. JAMA 2000, 284:1247-1255.
39. Briefing Package for NDA 21 389 [http://www.fda.gov/ohrms/ dockets/ac/05/briefing/2005-4090B1_31_AA-FDA-Tab-T.htm]
40. Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, et al.: TARGET Study Group. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: Randomised controlled trial. Lancet 2004, 364:675-684.
41. Mukherjee D: Selective cyclooxygenase inhibitors [COX-2] inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 2002, 63:817-821.
42. Grosser T, Fries S, FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006, 116:4-15.
43. Johnson AG, Nguyen TV, Day RO: Do non-steroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289-300.
44. ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone. JAMA 2000, 283:1967-1975.
45. Singh G, Miller JD, Huse DM, Pettitt D, D'Agostino RB, Russell MW: Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 2003, 30:714-719.